Compare Mesoblast Limited (MESO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Plby Group Inc — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while Plby Group Inc trades at $1.27 (market cap $162.94M). The key difference: Mesoblast Limited is far larger — about 13.6× Plby Group Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| MESO | PLBY | |
|---|---|---|
Market Cap | $2.21B | $162.94M |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $2.71 |
52-Week Low | $12.88 | $1.11 |
Enterprise Value | $2.21B | $308.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
PLBY trades at $1.18, down 3.28% recently, with a bearish technical signal. The company reported Q2 2026 revenue growth and positive operating cash flow, with net income turning positive in 2026 after years of losses. Valuation ratios like P/E of 68 and P/S of 1.2 appear elevated relative to profitability. Recent news highlights inclusion in Russell indexes and leadership expansion.
The outlook is cautiously optimistic with improving fundamentals, but high debt and thin margins pose risks. Analyst consensus is strongly bullish with 75% buy ratings, yet the stock faces execution risks in licensing growth and competitive pressures in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
